Core Insights - Avalo Therapeutics has appointed Paul Varki as Chief Legal Officer, enhancing its leadership team during a pivotal time following recent acquisition and private placement [1] - Varki brings over 20 years of experience in the pharmaceutical and biotech sectors, previously serving as US General Counsel at Idorsia Pharmaceuticals and holding various legal roles at other companies [1] - The appointment is expected to strengthen Avalo's strategic and legal capabilities, particularly in the development of AVTX-009 for hidradenitis suppurativa and other autoimmune conditions [1] Inducement Grants - As part of Varki's employment agreement, he has been granted a non-qualified stock option to purchase 150,000 shares of Avalo's common stock, vesting over four years with a twelve-month cliff [2] - The stock option was granted on June 24, 2024, with an exercise price equal to the closing price of Avalo's common stock on that date [2] Company Overview - Avalo Therapeutics is a clinical-stage biotechnology company focused on treating immune dysregulation, with its lead asset being AVTX-009, an anti-IL-1β monoclonal antibody targeting inflammatory diseases [3] - The company's pipeline also includes quisovalimab and AVTX-008, indicating a diverse approach to addressing autoimmune conditions [3] Product Details - AVTX-009 is a humanized monoclonal antibody that binds to interleukin-1β (IL-1β), a key driver in inflammatory processes, and is implicated in various autoimmune diseases [4] - The inhibition of IL-1β is considered a validated therapeutic target, with potential applications in dermatology, gastroenterology, and rheumatology [4]

Company Overview - Avalo Therapeutics, Inc. is a clinical stage biotechnology company focused on treating immune dysregulation [2] - The company's lead asset is AVTX-009, an anti-IL-1β monoclonal antibody targeting inflammatory diseases [2] - Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein) [2] Product Details - AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity, neutralizing its activity [3] - IL-1β is a central driver in the inflammatory process, and its overproduction is implicated in many autoimmune and inflammatory diseases [3] - Evidence suggests that inhibition of IL-1β could be effective in treating hidradenitis suppurativa and various inflammatory diseases in dermatology, gastroenterology, and rheumatology [3] Upcoming Events - Garry A. Neil, M.D., CEO and Chairman of the Board, will present on the Novel Immunological Mechanisms for Dermatological Disorders Panel at the Oppenheimer Novel Targets in Immunology Summit on June 24, 2024 [1]

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Avalo Therapeutics, Inc. (AVTX) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Avalo Therapeutics, Inc. is one of 1047 individual stocks in the Medical sector. Collectively, these companies sit at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-37590 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) 540 Gaither Road, Suite 400 Rockville, Maryland 20850 (Address of principal executive of ...

Exhibit 99.1 Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates • Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026 • Cash on hand of approximately $110 million as of March 31, 2024 with expected cash runway into 2027 WAYNE, PA AND ROCKVILLE, MD, May 13, 2024 — Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the first quarter of 2024. "Over the past month we have made considera ...

Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026Cash on hand of approximately $110 million as of March 31, 2024 with expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), today announced business updates and financial results for the first quarter of 2024. "Over the past month we have made considerable progress toward initiating our planned Phase 2 trial of AVTX-009 in hidraden ...

Avalo Therapeutics (AVTX) is a clinical-stage biotechnology company focused on developing therapies targeting immune dysregulation.In the past week, the company’s stock has skyrocketed 269.8%. This upside came after management made major strategic decisions and pivoted to its existing pipeline.Last week, Avalo announced that it completed the acquisition of privately-held AlmataBio. Post this acquisition, the company added an investigational anti-IL-1β monoclonal antibody (mAb), which it calls AVTX-009. Init ...

Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financing WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a team with ex ...

Avalo Therapeutics (AVTX) stock price nosedived on Monday after the company published relatively weak financial results. It tumbled by over 23.5% in the pre-market session and reached a low of $16.60. This plunge has lowered its market cap to about $19 million.Avalo Therapeutics earnings Copy link to section Avalo Therapeutics has made several headlines in the past few weeks. Last week, the company acquired AlmataBio in a stock deal valued at $22  million. This acquisition gave it AVTX-009, a phase 2-ready ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______to______ Commission File No. 001-37590 AVALO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or o ...